SCIENTIFIC PROGRAM


MELANOMA BRIDGE
December 3rd - December 5th, 2020
VIRTUAL MEETING




The program schedule has been defined to allow speakers to connect for live sessions considering the different time zones.


The Melanoma Bridge opening ceremony scheduled for December 3rd will be available on demand starting from the day after.


December 3rd 2020


MELANOMA BRIDGE OPENING SESSION**
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

09.20 PM Anti-cancer responses to the spectrum of “Cancer Antigens” and immune contraction**, Bernard A. Fox
09.40 PM The immune contexture for survival and immunotherapy response**, Jerome Galon






December 4th 2020


12.30 PM Introduction and objectives, Paolo A. Ascierto


Session - Melanoma as a model system
Chairpersons: Giuseppe Masucci, Magdalena Thurin

12.40 PM Targeting the microbiota in melanoma anti-PD1 therapy, Giorgio Trinchieri
12.55 PM Prediction of response to check point inhibition: is there a simple but not simplistic way? Iman Osman
01.10 PM Immunotherapy-induced anti-cancer responses, Bernard A. Fox
01.25 PM The role of CD39 in melanoma, Michele Teng
01.40 PM Discussion on Melanoma as a model system, Giuseppe Masucci, Magdalena Thurin
01.55 PM Break **
02.25 PM b Adrenergic Receptors: "A non-canonical Immune Checkpoint?", Marc Ernstoff
02.40 PM Escape mechanisms in melanoma, Soldano Ferrone
02.55 PM Electrochemotherapy in metastatic melanoma, Corrado Caracò
03.10 PM Uveal Melanoma, Richard D. Carvajal
03.25 PM Discussion on Melanoma as a model system, Giuseppe Masucci, Magdalena Thurin
03.40 PM SYMPOSIUM Target therapy in Melanoma
The role of target therapies in the treatment of Melanoma Braf positive between present and future, Paul Nathan, Paolo A. Ascierto
04.30 PM Break **


SESSION 3 MECHANISMS OF RESISTANCE AND DRIVERS OF RESPONSE
Chairpersons: Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri

04.45 PM SYMPOSIUM Adjuvant Therapy
Adjuvant therapy in melanoma: maximizing the chances for a cure Olivier Michielin, Paolo A. Ascierto
05.35 PM Translational research in the metastatic melanoma, Reinhard Dummer
05.50 PM Intrinsic tumor genomic and metabolic factors , Patrick Hwu
06.05 PM Achieving durable MAPK Suppression and Invigorating Anti-melanoma T Cell Immunity, Roger Lo
04.30 PM Break **
06.35 PM Tumor mutation burden and liquid biopsies, Claus Garbe
06.50 PM Mechanisms of resistance to cancer immunotherapy, Thomas F. Gajewski
07.05 PM T-cell intrinsic mechanisms of resistance to PD1 checkpoint blockade, Michelle Krogsgaard
07.20 PM Targeting dendritic cells to enhance the effectiveness of PD1 blockade against cold tumors, Pawel Kalinski
07.35 PM Discussion on Mechanisms of resistance and drivers of response, Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri






December 5th 2020




SESSION EMERGENT STRATEGIES
Chairpersons: Alexander M. Eggermont, Alessandro Testori

12.30 AM SYMPOSIUM IO and adjuvant therapy in melanoma
Adjuvant immunotherapy in melanoma: current practice and future directions, Georgina V. Long, Paolo A. Ascierto
01.20 PM Neoadjuvant Immunotherapy - less is more , Christian Blank
01.35 PM What are new ways to think about immunotherapy combinations for melanoma? Michael A. Postow
01.50 PM Considering QUAD therapy to address unmet needs in high risk BRAF mutant melanoma, Jason Luke
02.05 PM Break **
02.20 PM Development of novel antibodies targeting regulatory T cells in cancer, Sergio Quezada
02.35 PM Oncolytic virus combo with CKI- Ipi talimogene laherparepvec and talimogene laherparepvec+Pembrolizumab, Igor Puzanov
02.50 PM Exploring the potential of dendritic cell therapy for the treatment of advanced melanoma, from moDC to myDC, Bart Neyns
03.05 PM Discussion on Emergent strategies, Alexander M. Eggermont, Alessandro Testori
03.35 PM Break **


SESSION GREAT DEBATE
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

03.50 PM Is innate immunity important: yes or no? Jeffrey S. Weber, Alexander M. Eggermont
04.20 PM Discussion on "Is innate immunity important: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
04.30 PM Does AJCC classification an emprovement for better staging: yes or no? Jeffrey E. Gershenwald, Jean-Jacques Grob
05.00 PM Discussion on "Does AJCC classification an emprovement for better staging: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
05.10 PM Break **
05.25 PM Is the sentinel node biopsy useful for staging patient: yes or no? Vernon K. Sondak, Jean-Jacques Grob
05.55 PM Discussion on "Is the sentinel node biopsy useful for staging patient: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
06.05 PM Triplette combination (target therapy plus IO) VS combo IO Jeffrey A. Sosman, Michael B. Atkins
06.35 PM Discussion on "Triplette combination (target therapy plus IO) VS combo IO" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
06.45 PM Break **
07.00 PM Neoadjuvant or adjuvant therapy: which is better? Hussein A. Tawbi, Omid Hamid
07.30 PM Discussion on "Neoadjuvant or adjuvant therapy: which is better?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
07.40 PM What we will do on Monday? Sanjiv S. Agarwala
07.55 PM Conclusions Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
** Not included in the CME accredited program


For information please contact info@melanomabridge.org